Finance

Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Aug 24, 2025 - 20:00
 0  0
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0

Related Posts

Cracker Barrel faces social media pushback on new logo, brand refresh

Cracker Barrel faces social media pushback on new logo,...

Aug 22, 2025  0  0

Walmart will report earnings before the bell. Here's what to expect

Walmart will report earnings before the bell. Here's wh...

Aug 21, 2025  0  0

Spirit Airlines is on shakier ground after avoiding hard decisions in bankruptcy

Spirit Airlines is on shakier ground after avoiding har...

Aug 23, 2025  0  0

Beekeeping, boxing and budgets: Meet the finance chief who's about to lead WBD's networks offshoot

Beekeeping, boxing and budgets: Meet the finance chief ...

Aug 22, 2025  0  1

Tariffs aren't dealing a huge blow to big retailers and consumers — yet. Here are key earnings takeaways

Tariffs aren't dealing a huge blow to big retailers and...

Aug 22, 2025  0  0

John Deere faces a crossroads amid decreasing demand, increasing investments

John Deere faces a crossroads amid decreasing demand, i...

Aug 22, 2025  0  0